The Power and Pitfalls of Omics: George Davey Smith’s storming talk at ME/CFS conference
Read about the talk that stole the show at a recent ME/CFS conference in Simon McGrath's two-part blog.
Discuss the article on the Forums.

DAAO and GlyT1 inhibitors in treatment of Alzheimers, OCD, depression, schizophrenia, and more

Discussion in 'Detox: Methylation; B12; Glutathione; Chelation' started by pgoody, Jul 26, 2013.

  1. pgoody

    pgoody

    Messages:
    66
    Likes:
    33
    Here is an abstract that discusses the current thoughts behind this kind of treatment:

    https://www1.wfsbp-congress.org/guest/SciProgramSessionsList?SSN_ID=832

    Currently the top two GlyT1 inhibitors available are sarcosine (an endogenous inhibitor) and Bitopertin (which will be marketed come 2015?).

    D-amino acid oxidase (DAAO) inhibitors inhibit the breakdown of d-serine (and other D-amino acids). D-serine is an endogenous co-agonist of the NMDA glycine/d-serine site.

    A few more links:
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905773/ more in depth explanation

    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11058 for OCD
    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11023 for depression
    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11059 sodium benzoate, a potential DAAO inhibiting agent
    https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=12051 for Alzheimers

    There are likely other DAAO agents being tested, as I have read some material about this dating back at least 5 years. Sodium benzoate was something I just spotted on this particular site.
     

See more popular forum discussions.

Share This Page